Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25671490 | 0.85 | MGLL (0.30) | MGLL | |
| SCHEMBL13703574 | 0.82 | RIPK1 (0.31) | — | |
| SCHEMBL8354374 | 0.82 | MGLL (0.31) | MGLL | |
| SCHEMBL18914988 | 0.81 | ADORA3 (0.32) | L3MBTL1 | |
| SCHEMBL21713130 | 0.81 | DDB1 (0.34) | POLBALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL17447 | 0.80 | MGLL (0.37) | MGLL | |
| SCHEMBL18206807 | 0.80 | — | — | |
| SCHEMBL18932959 | 0.80 | — | — | |
| SCHEMBL18206808 | 0.80 | — | — | |
| SCHEMBL10106398 | 0.79 | NAMPT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554092-A | Method for preparing new drug building block (6-formylpyridin-3-yl) carbamic acid tert-butyl ester | 上海锐谱医药科技有限公司 | 2023-08-08 | — | — | CN | claimed |
| US-11028123-B2 | Capping of unprotected amino groups during peptide synthesis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2021-06-08 | — | — | US | claimed |
| CN-112218876-A | Synthesis of blocked lixisenatide | 赛诺菲-安万特德国有限公司 | 2021-01-12 | — | — | CN | claimed |
| US-20190330263-A1 | CAPPING OF UNPROTECTED AMINO GROUPS DURING PEPTIDE SYNTHESIS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2019-10-31 | — | — | US | claimed |
| EP-1218338-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-07-03 | — | — | EP | claimed |
| US-20020042536-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | ABBOTT LABORATORIES | 2002-04-11 | — | — | US | claimed |
| WO-2001027074-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-04-19 | — | — | WO | claimed |
| EP-4225762-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-121698848-B | Iron complex with triazacyclononane macrocyclic skeleton, and preparation method and application thereof | Quzhou Research Institute of Zhejiang University (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-3946460-B1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4676537-A1 | COMPOUNDS OF DRUGS WITH AN ALBUMIN BINDING MOIETY | Ascendis Pharma A/S (DK) | 2026-01-14 | — | — | EP | disclosed |
| WO-2001000582-A1 | PREPARATION OF QUINOLINE-SUBSTITUTED CARBONATE AND CARBAMATE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000005251-A1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-03 | — | — | WO | disclosed |
| EP-0741725-A1 | INDOLE DERIVATIVES AS 5-HT 1? AGONISTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| US-4714768-A | CHEMICAL INTERMEDIATES | AKADEMIE DER WISSENSCHAFTEN DER DDR (DD) | 1987-12-22 | — | — | US | disclosed |
| EP-0134041-A1 | N-Chlorocarbonyloxy-5-norbornene-2,3-dicarboximide, process for its preparation and its use | Akademie der Wissenschaften der DDR (DE) | 1985-03-13 | — | — | EP | disclosed |
| US-4399131-A | Cephem derivatives | HOECHST AG (DE) | 1983-08-16 | — | — | US | disclosed |
| US-4126628-A | BASIC CATALYST | CANADIAN PATENTS AND DEVELOPMENT LIMITED (CA) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612416-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, CLCN2, CLIC1 | ELANE 818/4885CHRM2 70/4885CHRM1 155/4885 |
| US-20190330263-A1 | CAPPING OF UNPROTECTED AMINO GROUPS DURING PEPTIDE SYNTHESIS | RNGTT, ANPEP, DNPEP | ELANE 1716/4885CHRM2 4777/4885CHRM1 4289/4885 |
| US-20020042536-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | DNPEP, PHYKPL, KARS1 | ELANE 2179/4885CHRM2 3332/4885CHRM1 2802/4885 |
| US-11028123-B2 | Capping of unprotected amino groups during peptide synthesis | RNGTT, ANPEP, DNPEP | ELANE 1716/4885CHRM2 4777/4885CHRM1 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.